<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20261012071406N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-10-14</date_registration>
      <primary_sponsor>University of social welfare and rehabilitation sciences</primary_sponsor>
      <public_title>Effect of a Psychological Intervention Mobile Application on Treatment Adherence in Individuals with Type 2 Diabetes</public_title>
      <acronym></acronym>
      <scientific_title>To evaluate the efficacy of a psychological intervention mobile application in improving treatment adherence in individuals with type 2 diabetes.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2027-07-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>120</target_size>
      <recruitment_status>Pending</recruitment_status>
      <url>https://irct.ir/trial/94035</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Education/Guidance, Randomization description: All participants will first undergo a baseline assessment. They will then be randomly assigned to either the intervention or the control group using block randomization. The allocation sequence will be generated in Microsoft Excel using block randomization with a 1:1 allocation ratio. Possible sequences containing equal numbers of assignments to the intervention and control groups within each block will be selected using a random number generation function. The final sequence will be saved before participants are allocated.</study_design>
      <phase>N/A</phase>
      <hc_freetext>type 2 diabetes.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Participants in the intervention group will use a psychological intervention mobile application for four months alongside usual diabetes care. The application provides education, personalized motivational and psychological interventions, reminders, and recording and monitoring of medication use, blood glucose, diet, and physical activity. Training on application use and technical support will also be provided. Intervention 2: Control group: Participants in the control group will receive usual diabetes care under the supervision of their treating physician for four months, without using the psychological intervention mobile application being evaluated.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is To protect participants’ confidentiality and privacy, there is no plan to share individual participant data, even in de-identified form.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Somayeh Azizi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 122, Falsafi Ave, Kooy-e Bimeh, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1393845315</zip>
        <telephone>+98 21 4469 8591</telephone>
        <email>som.azizi@uswr.ac.ir</email>
        <affiliation>University of social welfare and rehabilitation sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Somayeh Azizi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 122, Falsafi Ave, Kooy-e Bimeh, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1393845315</zip>
        <telephone>+98 21 4469 8591</telephone>
        <email>som.azizi@uswr.ac.ir</email>
        <affiliation>University of social welfare and rehabilitation sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Diagnosis of type 2 diabetes: Type 2 diabetes diagnosed by an endocrinologist.
Insufficient treatment adherence: A score below 45 on the Summary of Diabetes Self-Care Activities (SDSCA) measure and below 6 on the eight-item Morisky Medication Adherence Scale (MMAS-8).
Age: Between 20 and 55 years.
Ability to use the application: Basic digital literacy and the ability to install, use, and update the application.
Access to a smartphone: Access to a stable internet connection (Wi-Fi or mobile data) and enabled GPS for location-based features.
No participation in other ongoing studies or use of similar applications.</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>55 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Physical or psychological limitations affecting the ability to use the application: Individuals who lack sufficient physical or psychological capacity to use the application, including those with neurological conditions, cognitive impairments, psychiatric disorders requiring medication, or severe visual impairments, are not eligible to participate.
Pregnancy or breastfeeding: Pregnant or breastfeeding women are not eligible due to the metabolic changes that may occur during pregnancy or breastfeeding.
Other severe chronic diseases: Individuals with other severe chronic diseases, such as cancer, heart disease, or kidney failure, are not eligible, as these conditions may confound the effects related to diabetes or lead to deterioration in health during the study.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E11</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Type 2 diabetes mellitus</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Behavior</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Participants in the intervention group will use a psychological intervention mobile application for four months alongside usual diabetes care. The application provides education, personalized motivational and psychological interventions, reminders, and recording and monitoring of medication use, blood glucose, diet, and physical activity. Training on application use and technical support will also be provided.</i_keyword>
      <i_keyword>Control group: Participants in the control group will receive usual diabetes care under the supervision of their treating physician for four months, without using the psychological intervention mobile application being evaluated</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Medication adherence. Timepoint: In both groups, at baseline (before the intervention begins), and at two and four months after the start of the intervention. Method of measurement: Eight-item Morisky Medication Adherence Scale.</prim_outcome>
      <prim_outcome>Diabetes self-care behaviors. Timepoint: In both groups, at baseline (before the intervention begins), and at two and four months after the start of the intervention. Method of measurement: Summary of Diabetes Self-Care Activities measure.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Glycated hemoglobin level. Timepoint: In both groups, at baseline (before the intervention begins), and at two and four months after the start of the intervention. Method of measurement: Blood testing to measure glycated hemoglobin levels, based on participants’ laboratory results.</sec_outcome>
      <sec_outcome>Number of blood glucose readings outside the target range. Timepoint: In both groups, at baseline (before the intervention begins), and at two and four months after the start of the intervention. Method of measurement: Counting blood glucose readings outside the target range in the recorded data.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>University of social welfare and rehabilitation sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-04-30</approval_date>
        <contact_name>Research Ethics Committees of University of Social Welfare and Rehabilitation Sciences</contact_name>
        <contact_address>University of Social Welfare and Rehabilitation Sciences, Koodakyar Alley, Daneshjoo Ave. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
